abstract |
The present disclosure relates to non-CpG single-stranded oligonucleotides (ssONs) with broad-spectrum antiviral activity for use in the treatment and/or prophylaxis of viral infections, such as Herpes simplex virus, Ebola virus, Lassa virus, Lyssa virus, rabies virus, measles virus, vesicular stomatitis virus (VSV), murine leukemia virus (MLV) and HIV-1, as well as multi-resistant HIV-1 infections, in a subject. Said ssONs have a length of at least 25 nucleotides and are stabilized by phosphorothioate internucleotide linkages and/or 2'-O-Methyl modifications. |